OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2023.13659 OL-25-2-13659 Articles Clinicopathological and prognostic value of long non-coding RNA CCAT1 expression in patients with digestive system cancer YuYue 1 * XuZhihua 1 * NiHao 2 * JinMengxian 3 DaiChen 4 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China Department of Endocrinology, Suzhou Xiangcheng People's Hospital, Suzhou, Jiangsu 215131, P.R. China Department of Thyroid and Breast Surgery, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China Correspondence to: Dr Mengxian Jin, Department of Endocrinology, Suzhou Xiangcheng People's Hospital, 1060 Huayuan Road, Xiangcheng, Suzhou, Jiangsu 215131, P.R. China, E-mail: szjmx1991@163.com Dr Chen Dai, Department of Thyroid and Breast Surgery, Ningbo First Hospital, 59 Liu Ting Street, Haishu, Ningbo, Zhejiang 315010, P.R. China, E-mail: doushidada@163.com

Contributed equally

 02 2023 02 01 2023 25 2 73 05052022 09112022 Copyright: © Yu et al. 2023 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Colon cancer associated transcript-1 (CCAT1) is known to play an important role in numerous types of human cancer, including bladder, prostate and ovarian cancer. However, a consistent perspective has not been established in digestive system cancer (DSC). To explore the prognostic value of CCAT1 in patients with DSC, a meta-analysis was performed. A systematic search of PubMed, Embase, Web of Science, China National Knowledge Infrastructure, Chinese Biological Medical Literature database, Cochrane Library and WanFang database was applied to select eligible articles. Pooled odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to estimate the effects of CCAT1 on pathological or clinical features. A total of 1,719 patients from 12 eligible articles were enrolled in the meta-analysis. The results revealed that elevated CCAT1 expression was significantly related to larger tumor size (OR, 1.81; 95% CI, 1.31-2.48), poorer differentiation (OR, 0.45; 95% CI, 0.31-0.64), earlier lymph node metastasis (OR, 3.14; 95% CI, 2.34-4.22) and advanced TNM stage (OR, 3.08; 95% CI, 2.07-4.59). In addition, high CCAT1 expression predicted a poorer outcome for overall survival rate (HR, 2.37; 95% CI, 2.11-2.67) and recurrence-free survival rate (HR, 2.16, 95% CI, 1.31-3.57). High expression levels of CCAT1 were therefore related to unfavorable clinical outcomes of patients with DSC. These results demonstrated that CCAT1 could serve as a prognostic predictor in human DSC.

 CCAT1 digestive system cancer clinicopathological parameter prognosis meta-analysis Funding: No funding was received. Introduction

Cancer has been a leading cause of disease-related deaths worldwide over the past decade (1). Digestive system cancer (DSC) is responsible for more deaths from cancer than cancer of any other system. Three out of five of the world's major sources of cancer-related death are from digestive system tumors (2). Although radiotherapy, chemotherapy, individualized precision therapy and immunotherapy have been developed for cancer diagnosis and treatment, the 5-year survival rate of patients with DSC remains poor (3,4). Recently, it has been established that numerous biomarkers, including des-γ-carboxyprothrombin, miR-12 and miR-15b, associated with tumor screening, diagnosis and prognosis, play significant roles in the development of DSC (5–7). However, only a small portion of these biomarkers is well accepted for clinical usage (8). This may be due to low specificity, sensitivity or consistency in tumor development. Therefore, it is clinically necessary and urgent to develop novel prognostic biomarkers for DSC.

Long non-coding RNAs (lncRNAs) are defined as non-protein coding RNAs that are >200 nucleotides and do not contain an open reading frame (9). Abnormal expression of lncRNAs is observed in various types of cancer, including breast, colorectal and lung cancer, and these lncRNAs are involved in tumorigenesis and progression through interactions with DNA, mRNA, microRNA (miR/miRNA) and proteins (10–12). In previous years, increasing evidence has suggested that lncRNAs, such as LINC00645 (13), LINC01133 (14), long non-coding RNA regulating IL-6 transcription (15) and growth arrest-specific 5 transcript (16), may serve as novel prognostic biomarkers and potential therapeutic targets for human cancer.

Colon cancer associated transcript-1 (CCAT1), a nuclear-restricted lncRNA located on chromosome 8q24.21, was first identified as an oncogene in colorectal cancer by Nissan (17). Overexpression of CCAT1 was found in various types of cancer and attracted the attention of a number of researchers due to its prognostic value (18–20). You et al (21) found that CCAT1 was overexpressed in prostate cancer tissue samples and cell lines, and promoted cell proliferation, which indicated that CCAT1 might suggest an unfavorable outcome for the patient. Similarly, an investigation by Shen et al (22) suggested that CCAT1 was a key oncogenic lncRNA correlated with cervical cancer and played an important role in promoting cervical cancer progression via regulation of the miR-181a-5p/MMP14 axis. Moreover, Han et al (23) discovered that CCAT1 was upregulated in triple-negative breast cancer tissues, and patients with high CCAT1 expression had shorter overall survival (OS) times compared with those patients with low expression. A review by Wang et al (24) summarized that CCAT1 was associated with clinicopathological features, recurrence-free survival (RFS) and OS rates in patients, and that CCAT1 could serve as a diagnostic and prognostic marker in various types of human cancer, including gallbladder cancer, cholangiocarcinoma and pancreatic cancer. However, due to the relatively small sample size, these studies on CCAT1 were moderately limited, and there was no research to systematically clarify the prognostic value of CCAT1 in DSC. Therefore, the meta-analysis in the present study aimed to systematically evaluate the clinicopathological and prognostic role of CCAT1 in patients with DSC.

 Materials and methods <sec> <title>Search strategy and literature selection

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were strictly followed during the meta-analysis (25).

A systematic search was performed using PubMed (https://pubmed.ncbi.nlm.nih.gov/), Embase (https://www.embase.com), Web of Science (https://www.webofscience.com), China National Knowledge Infrastructure (https://en.cnki.com.cn), Cochrane Library (https://www.cochranelibrary.com/), Chinese Biological Medical Literature database (http://www.sinomed.ac.cn/zh/) and WanFang database (https://www.wanfangdata.com.cn). The search terms used for literature retrieval were as follows: ‘colon cancer associated transcript-1’ or ‘colon cancer associated transcript 1’ or ‘CCAT1’ or ‘lncRNA CCAT1’ and ‘digestive system’ and ‘cancer’ or ‘tumor’ or ‘neoplasm’ or ‘carcinoma’ or ‘malignancy’. Articles were searched from the creation of each database to March 31, 2022. Articles eligible for this study were updated on April 10, 2022.

The initial database search yielded 355 articles according to the search strategy. After screening the titles and abstracts, 256 literature studies were eliminated due to article duplication. The remaining 99 articles were quickly browsed, and 47 articles were excluded, as they were reviews, conference summaries or comments. Following a further assessment of the remaining 52 articles, 40 articles were excluded, as they did not analyze enough samples or extract data. Finally, 12 articles with a total of 1,719 patients qualified for the present study. Among the 12 included, 1 article was published in 2014, 4 in 2015, 1 in 2016, 5 in 2017 and 1 in 2020. The time range of the studies used for the meta-analysis was therefore 2014-2020. The details of the screening process are shown in Fig. 1.

 Inclusion and exclusion criteria

Inclusion criteria were as follows: i) Expression levels of CCAT1 were detected in human DSC; ii) the method of detecting CCAT1 expression was reverse transcription-quantitative PCR (RT-qPCR); iii) the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were reported directly or could be calculated from Kaplan-Meier survival curves; iv) evaluation of a relationship between high/low CCAT1 expression and clinical outcomes; v) results included clinicopathological features or survival rate (OS or RFS); vi) available full-text articles; and vii) articles were published in English.

Exclusion criteria were as follows: i) Duplicate publications; ii) studies missing a control group; iii) no data could be extracted and/or the studies were published as reviews, abstracts, comments, case reports, expert opinions letters or editorials; iv) non-human studies; v) articles missing OS or RFS data; vi) small sample size (total patients <20); vii) articles not published in English; and viii) HRs could not be calculated from the published data.

 Data extraction and quality assessment

All data and usable information were screened and extracted by 2 independent investigators. For all included studies, the following information was collected: First author, country of research, publication date, type of cancer, number of patients, CCAT1 detection method, clinicopathological parameters, survival analysis and outcome measure. Newcastle-Ottawa Scale (NOS) criteria were employed to evaluate the quality of each included study (26). Studies with an NOS score ≥6 were considered to be of high quality; otherwise, they were defined as low quality. All the studies included in the present meta-analysis were considered as high quality.

 Statistical analysis

The statistical analyses were performed using STATA 14.0 software (StataCorp LP). Statistical analysis with a two-sided P-value of <0.05 was considered statistically significant. The original study aims were divided into two categories in the meta-analysis. The first aim was to assess the correlation of high CCAT1 expression with clinicopathological characteristics, including age, sex, depth of infiltration, tumor size, histological differentiation, lymph node metastasis and TNM stage. The characteristic standards were based on the latest guidelines by the publication date (27–29). Pooled odds ratios (ORs) with corresponding 95% CIs were used to evaluate the association between CCAT1 expression and clinicopathological parameters. Q test and I2 test were used to assess the statistical heterogeneity. Heterogeneity was considered present when I2>50% or P<0.05 for the Q test. A random effects model was used to analyze the data, as heterogeneity was expected for the intervention effects among multiple studies from different groups and geographical locations. The second aim was to evaluate the prognostic value of CCAT1 on OS and RFS with HRs and corresponding 95% CIs. HRs with corresponding 95% CIs were calculated by the survival data extracted from Kaplan-Meier curves with Engauge Digitizer version 4.1 (https://markummitchell.github.io/engauge-digitizer/) when not directly presented in articles. The standard error (SE) of the HR was computed using lnhr and the upper (lnul) and lower limit (lnll) of the CIs, taking the mean of the SE of the lnll and lnul, and selnhr=(lnul-lnll)/(1.96×2). Begg's test was performed to assess the potential publication bias, and P<0.05 was considered to indicate a statistically significant difference. The sensitivity analysis was performed to assess the reliability of the meta-analysis. STATA 14.0 software (Stata Corp LLC) was used for the sensitivity analysis, which was performed by excluding studies one by one and observing whether the heterogeneity changed.

 Results <sec> <title>Characteristics of eligible studies

A total of 12 eligible studies (30–41) focusing on DSC (1 on colon cancer, 1 on esophageal squamous cell carcinoma, 2 on cholangiocarcinoma, 2 on gastric cancer, 3 on colorectal cancer and 3 on hepatocellular carcinoma) were enrolled in the present meta-analysis. The basic information and characteristics of each study are summarized in Tables I and II. Among the included studies, 2 came from the USA and the rest were from China. The expression levels of CCAT1 were examined by RT-qPCR in all studies. The median expression levels of CCAT1 in the studies conducted by He et al (30), Zhu et al (31) and Deng et al (33) were regarded as the cut-off values, while the mean expression levels were set as the cut-off values in the studies conducted by Zhang et al (38) and Li et al (40). The cut-off value in the study conducted by Liu and Shangguan (32) was 0.041 and the setting standard was not introduced. However, the other eligible articles did not report the cut-off value. Of the 12 studies, 9 provided OS information, 4 presented RFS information and 1 presented DFS information. Moreover, the included studies were published from 2014 to 2020 with a sample size ranging from 48 to 638.

 Correlation of CCAT1 expression with clinicopathological characteristics

The association between CCAT1 expression and clinicopathological characteristics was assessed in 12 studies with six types of DSC. As shown in Figs. 2 and 3, and Table III, high CCAT1 expression levels were significantly associated with larger tumor size (>5 cm vs. ≤5 cm; OR, 1.81; 95% CI, 1.31-2.48; P<0.001; Fig. 2D), poorer differentiation (high and moderate vs. low; OR, 0.45; 95% CI, 0.31-0.64; P<0.001; Fig. 3A), earlier lymph node metastasis (yes vs. no; OR, 3.14; 95% CI, 2.34-4.22, P<0.001; Fig. 3B) and advanced TNM stage (III+IV vs. I+II; OR, 3.08; 95% CI, 2.07-4.59, P<0.001, Fig. 3C). However, no significant association was found with age (≥60 vs. <60; OR, 0.91; 95% CI, 0.73-1.12; P=0.369; Fig. 2A), sex (male vs. female; OR, 1.16; 95% CI, 0.95-1.42; P=0.156; Fig. 2B) and depth of infiltration (T3+4 vs. T1+2; OR, 1.95; 95% CI, 0.79-4.84; P=0.147; Fig. 2C).

 Association between CCAT1 expression and OS

The studies containing OS rate data covered 1,481 patients. A random effects model was applied to calculate the pooled HRs and the respective 95% CIs. Subsequently, the result suggested that CCAT1 expression had a significant effect on OS (pooled HR, 2.35; 95% CI, 2.08-2.63; Fig. 4 and Table IV), in which higher expression of CCAT1 was associated with a poorer OS outcome.

 Association between CCAT1 expression and RFS

A total of 4 studies comprising 191 subjects reported the RFS based on CCAT1 expression levels in patients with DSC (Fig. 4 and Table IV). The pooled HR was 2.27 (95% CI, 1.31-3.23) with no significant heterogeneity (I2=0.0%; P=0.932). This suggested that patients with high CCAT1 expression tended to have shorter RFS times compared with those patients with low CCAT1 expression.

 Publication bias

To assess the potential publication bias, Begg's funnel analysis was performed. As shown in Figs. 5 and 6, there was no publication bias for age (P=0.602), sex (P=0.533), depth of infiltration (P=0.089), tumor size (P=0.060), differentiation (P=1.000), lymph node metastasis (P=0.072), TNM stage (P=0.210) and OS (P=0.076).

 Sensitivity analysis

A sensitivity analysis was conducted to detect the influence of an individual study on the pooled results by omitting a single study each time (Figs. 7 and 8). The results verified that any individual study could not significantly change the pooled estimates, revealing that the results of the synthetic analysis were stable and credible.

 Discussion

DSC, consisting mainly of esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, gallbladder cancer and pancreatic cancer, has become a health burden with high mortality worldwide, and a marked increase in incidence has been observed (42,43). Traditionally, clinicopathological variables, such as tumor size, depth of infiltration, differentiation, lymph node metastasis and TNM stage, are applied to predict the survival outcome of patients with DSC (7). Early stage DSC has a significantly improved survival outcome compared with advanced-stage DSC, in which tumor invasion and metastasis are common pathological characteristics of a poor prognosis (44). Thus, seeking new tumor biomarkers or therapeutic targets to increase the survival rate of patients with DSC has become the key to clinical work (45). Emerging evidence has revealed that lncRNAs have become a topic of interest due to their functions in a variety of biological processes, and the alteration of lncRNA expression could result in abnormal expression of gene products, cellular differentiation, protein localization and DNA damage response, leading to the occurrence and development of cancer (12,46). In a previous study, aberrant expression of lncRNAs was related to clinical outcomes for patients with cancer, and could be tracked in numerous malignant biological behaviors, including proliferation, invasion, migration, the cell cycle, apoptosis and angiogenesis, which indicated the potential roles of lncRNAs as biomarkers or therapeutic targets in cancer (47). Moreover, due to great specificity, sensitivity and convenient detection in bodily fluids, lncRNAs have significant potential to be a promising biomarker for the early detection and accurate survival outcome prediction of patients with DSC.

The lncRNA CCAT1 has been found to be upregulated in different types of cancer (17). Recently, emerging studies suggested that CCAT1 participated in multiple cellular processes involved in DSC, such as cell proliferation, invasion and drug resistance, by targeting mRNAs, regulating miRNAs or competing with endogenous RNAs (48–50). Zhang et al (51) demonstrated that CCAT1 could regulate the expression of CCNE1 by acting as a competing endogenous RNA to sponge miR-30c-2-3p, thereby regulating the cell proliferation and metastasis of hepatocellular carcinoma (HCC), indicating that CCAT1 might be a novel therapeutic target for HCC. An investigation by Fang et al (52) found that the expression of CCAT1 in gastric cancer tissues was higher than that in adjacent tumor tissues, and CCAT1 could promote the metastasis of gastric cancer by epithelial-mesenchymal transition. Similarly, a study by Li et al (53) revealed that CCAT1 upregulation could promote cell proliferation and migration by affecting Bmi-1 expression in gastric cancer. In addition, Hu et al (54) demonstrated that CCAT1 could influence the cell proliferation and drug resistance of esophageal cancer by inhibiting the miR-143/PLK1/BUBR1 axis, and that CCAT1 could be a potential biomarker for esophageal cancer. Together, these studies revealed that CCAT1 could be a potential prognostic biomarker for DSC.

In order to clarify the association of CCAT1 expression levels with clinicopathological features and patient survival in DSC, the present meta-analysis was performed. A previous meta-analysis reported that CCAT1 expression was related to certain clinicopathological variables (tumor size, lymph node metastasis, TNM stage, distant metastasis, microvascular invasion and capsular formation) in all types of cancer, and had a predictive value for a poor prognosis of cancer (55), which was consistent with the present study conclusions. In contrast to the previous study, digestive system tumors were analyzed in the present study rather than all tumor types. In the present meta-analysis, a total of 1,719 patients from 12 studies were enrolled. The random effects model was applied for analyzing the relationship between CCAT1 expression and clinicopathological variables, including age, sex, tumor size, differentiation and lymph node metastasis. Due to the presence of moderate heterogeneity among the studies in terms of depth of infiltration (P=0.006; I2=75.9%) and TNM stage (P=0.005; I2=62.0%), a random effects model was used to pool data. It was observed that 4 studies had significant statistical heterogeneity for depth of infiltration and 10 studies for TNM stage. This heterogeneity might be the result of design discrepancies for depth of infiltration among the studies. The heterogeneity for TNM stage might be due to the different staging criteria being used by the studies. Most studies did not introduce the staging criteria they used. The results demonstrated that increased expression of CCAT1 was significantly related to larger tumor size (OR, 1.81; 95% CI, 1.31-2.48), poorer differentiation (OR, 0.45; 95% CI, 0.31-0.64), earlier lymph node metastasis (OR, 3.14; 95% CI, 2.34-4.22) and advanced TNM stage (OR, 3.08; 95% CI, 2.07-4.59). However, no significant association was observed between the expression of CCAT1 and other clinicopathological features, including age, sex and depth of infiltration. In addition, considering the survival rate of patients, the association between the expression level of CCAT1 and the prognosis of patients with DSC was clarified. The results showed that elevated CCAT1 expression was associated with poor OS (HR, 2.37; 95% CI, 2.11-2.67) and RFS (HR, 2.16; 95% CI, 1.31-3.57). Moreover, Begg's funnel analysis was conducted to estimate the underlying publication bias. The result indicated that there was no significant publication bias for age, sex, depth of infiltration, tumor size, differentiation, lymph node metastasis, TNM stage and OS. The sensitivity analysis suggested that each individual study could not influence the conclusions significantly, indicating the robustness of the results.

Although the association between CCAT1 expression and the prognosis of patients with DSC was comprehensively evaluated, there were still some limitations in the present meta-analysis. Firstly, the lack of further refinement in the research strategy due to the digestive system tumors being analyzed as a whole, and not also as separate cancer entities (e.g., colorectal, gastric and esophageal cancer), was a major limitation of the present study. Secondly, most studies were from China, and only 2 articles were from the USA, which may not fully represent the conclusions of all countries, and diminished the overall effect of the results. On the one hand, it might be that through the inclusion and exclusion criteria, only articles published in English were used, which led to relevant studies in other countries not being included. On the other hand, in recent years, the incidence of DSC in China has gradually increased (56). It is possible that some eating habits are high-risk factors for the occurrence of DSC, leading to more articles on DSC in China than in other countries. Thirdly, the number of patients enrolled in some studies was relatively small, and the studies could not cover all types of DSC. Fourthly, some of the HRs were calculated by reconstructing survival curves rather than being directly obtained from the primary data. Fifthly, most enrolled studies presented positive results, and those with negative results were less likely to be published. Sixthly, the cut-off value of CCAT1 expression levels in each study had its own criteria (median or mean), which meant that there was no consensus on the cut-off estimates for differentiating high or low CCAT1 expression. Finally, the biological features and molecular mechanisms associated with different types of DSC may generate potentially inconsistent results. However, in the present study, there was still scope to analyze the existing CCAT1 articles and explore the clinical significance of CCAT1 in DSC. It is hoped that there will be more relevant studies of CCAT1 from other countries and high-quality studies involving large numbers of patients in the future, which will further strengthen the present findings and will enhance the understanding of CCAT1 in DSC and its possible mechanisms.

CCAT1 could serve as a potential biomarker for the prognosis of patients with DSC and potentially participate in DSC development and progression. Importantly, the present study sheds some light on the clinical and molecular mechanisms underlying the pathogenesis of DSC and facilitates the understanding of novel therapeutic targets in DSC. Therefore, more relevant studies that meet the requirements should be included in future studies to further evaluate the value of CCAT1 in the prognosis of DSC, so as to provide more sufficient and powerful evidence-based medical results and guide clinical medical work. A comprehensive prognosis should be based on a combination of multiple prognostic approaches to improve the accuracy. Furthermore, more well-designed studies involving all types of DSC are needed to verify the prognostic value of CCAT1 in DSC. In future, the mechanism of CCAT1 expression from the perspective of molecular and epigenetics should be explored, and the tissue specificity of CCAT1 expression in different histological types of tumors should be validated.

 Acknowledgements

Not applicable.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

ZHX conceived and designed the study. YY collected and analyzed the data, and drafted the paper. CD and MXJ helped with the data analysis and manuscript revision. YY and HN analyzed the data and revised the final paper. ZHX and CD confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References HuJNiGMaoLXueXZhangJWuWZhangSZhaoHDingLWangLLINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axisOnco Targets Ther1278657875201910.2147/OTT.S18947131576144 SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalABrayFGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin71209249202110.3322/caac.2166033538338 JiangJMaTXiWYangCWuJZhouCWangNZhuZZhangJPre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapyCancer Manag Res1186578668201910.2147/CMAR.S21108931576170 FiorilloCQueroGAlfieriSResection margin status in pancreatic cancer surgery: Is it really less important than the N status?Br J Surg1061559201910.1002/bjs.1135631577052 AyoubWSSteggerdaJYangJDKuoASundaramVLuSCCurrent status of hepatocellular carcinoma detection: Screening strategies and novel biomarkersTher Adv Med Oncol111758835919869120201910.1177/175883591986912031523283 SalatiMOrsiGSmythEAprileGBerettaGDe VitaFDi BartolomeoMFanottoVLonardiSMoranoFGastric cancer: Translating novels concepts into clinical practiceCancer Treat Rev79101889201910.1016/j.ctrv.2019.10188931445415 SerraOGalánMGinestaMMCalvoMSalaNSalazarRComparison and applicability of molecular classifications for gastric cancerCancer Treat Rev772934201910.1016/j.ctrv.2019.05.00531195213 NeculaLMateiLDraguDNeaguAIMambetCNedeianuSBleotuCDiaconuCCChivu-EconomescuMRecent advances in gastric cancer early diagnosisWorld J Gastroenterol2520292044201910.3748/wjg.v25.i17.202931114131 López-UrrutiaEBustamante MontesLPLadrón de Guevara CervantesDPérez-PlasenciaCCampos-ParraADCrosstalk between long non-coding RNAs, Micro-RNAs and mRNAs: Deciphering molecular mechanisms of master regulators in cancerFront Oncol9669201910.3389/fonc.2019.0066931404273 ShangWAdzikaGKLiYHuangQDingNChinembiriBRashidMSMachukiJOMolecular mechanisms of circular RNAs, transforming growth factor-β, and long noncoding RNAs in hepatocellular carcinomaCancer Med866846699201910.1002/cam4.255331523930 LiMYTangXHFuYWangTJZhuJMRegulatory mechanisms and clinical applications of the long non-coding RNA PVT1 in cancer treatmentFront Oncol9787201910.3389/fonc.2019.0078731497532 ChiYWangDWangJYuWYangJLong non-coding RNA in the pathogenesis of cancersCells81015201910.3390/cells809101531480503 LiCZhengHHouWBaoHXiongJCheWGuYSunHLiangPLong non-coding RNA linc00645 promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-205-3p-ZEB1 axis in gliomaCell Death Dis10717201910.1038/s41419-019-1948-831558707 SongZZhangXLinYWeiYLiangSDongCLINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2J Cell Mol Med2375547565201910.1111/jcmm.1462531557401 WangJZhouJJiangCZhengJNambaHChiPAsakawaTLNRRIL6, a novel long noncoding RNA, protects colorectal cancer cells by activating the IL-6-STAT3 pathwayMol Oncol1323442360201910.1002/1878-0261.1253831246342 LiWLiNShiKChenQSystematic review and meta-analysis of the utility of long non-coding RNA GAS5 as a diagnostic and prognostic cancer biomarkerOncotarget86641466425201710.18632/oncotarget.1904029029523 NissanAStojadinovicAMitrani-RosenbaumSHalleDGrinbaumRRoistacherMBochemADayancBERitterGGomceliIColon cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissuesInt J Cancer13015981606201210.1002/ijc.2617021547902 Ghafouri-FardSTaheriMColon cancer-associated transcripts 1 and 2: Roles and functions in human cancersJ Cell PhysiolJan282019(Epub ahead of print)10.1002/jcp.28176 GuoXHuaYCCAT1: An oncogenic long noncoding RNA in human cancersJ Cancer Res Clin Oncol143555562201710.1007/s00432-016-2268-327638771 ZhangCWangWLinJXiaoJTianYlncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasionInt Braz J Urol45549559201910.1590/s1677-5538.ibju.2018.045031038865 YouZLiuCWangCLingZWangYWangYZhangMChenSXuBGuanHChenMLncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and MIR-28-5PMol Cancer Ther1824692479201910.1158/1535-7163.MCT-19-009531387890 ShenHWangLXiongJRenCGaoCDingWZhuDMaDWangHLong non-coding RNA CCAT1 promotes cervical cancer cell proliferation and invasion by regulating the miR-181a-5p/MMP14 axisCell Cycle1811101121201910.1080/15384101.2019.160982931084453 HanCLiXFanQLiuGYinJCCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signalingAging (Albany NY)1148584875201910.18632/aging.10208031310241 WangNYuYXuBZhangMLiQMiaoLPivotal prognostic and diagnostic role of the long non-coding RNA colon cancer-associated transcript 1 expression in human cancer (review)Mol Med Rep19771782201930535444 MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statementJ Clin Epidemiol6210061012200910.1016/j.jclinepi.2009.06.00519631508 SeitzAKChristensenLLChristensenEFaarkrogKOstenfeldMSHedegaardJNordentoftINielsenMMPalmfeldtJThomsonMProfiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancerSci Rep7395201710.1038/s41598-017-00327-028341852 WeiserMRAJCC 8th edition: Colorectal cancerAnn Surg Oncol2514541455201810.1245/s10434-018-6462-129616422 ChunYSPawlikTMVautheyJN8th Edition of the AJCC cancer staging manual: Pancreas and hepatobiliary cancersAnn Surg Oncol25845847201810.1245/s10434-017-6025-x28752469 TsoukalasNTsapakidisKKamposiorasKAJCC-8 TNM staging system for gastric cancerIs there a scope for improvement? J Invest Surg33939940202010.1080/08941939.2019.157928030892116 HeXTanXWangXJinHLiuLMaLYuHFanZC-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasionTumour Biol351218112188201410.1007/s13277-014-2526-425185650 ZhuHQZhouXChangHLiHGLiuFFMaCQLuJAberrant expression of CCAT1 regulated by c-Myc predicts the prognosis of hepatocellular carcinomaAsian Pac J Cancer Prev1651815185201510.7314/APJCP.2015.16.13.518126225650 LiuJNShangguanYMLong non-coding RNA CARLo-5 upregulation associates with poor prognosis in patients suffering gastric cancerEur Rev Med Pharmacol Sci21530534201710.1016/j.ejps.2016.10.02428239816 DengLYangSBXuFFZhangJHLong noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 spongeJ Exp Clin Cancer Res3418201510.1186/s13046-015-0136-725884472 JiangXMLiZLLiJLZhengWYLiXHCuiYFSunDJLncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinomaEur Rev Med Pharmacol Sci2112421247201728387907 OzawaTMatsuyamaTToiyamaYTakahashiNIshikawaTUetakeHYamadaYKusunokiMCalinGGoelACCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancerAnn Oncol2818821888201710.1093/annonc/mdx24828838211 WangFXieCZhaoWDengZYangHFangQLong non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patientsClin Exp Med173343201710.1007/s10238-015-0395-926433964 McClelandMLMeshKLorenzanaEChopraVSSegalEWatanabeCHaleyBMaybaOYaylaogluMGnadFFiresteinRCCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancerJ Clin Invest126639652201610.1172/JCI8326526752646 ZhangEHanLYinDHeXHongLSiXQiuMXuTDeWXuLH3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinomaNucleic Acids Res4530863101201710.1093/nar/gkw124727956498 ZhangSXiaoJChaiYDuYYLiuZHuangKZhouXZhouWLncRNA-CCAT1 promotes migration, invasion, and EMT in intrahepatic cholangiocarcinoma through suppressing miR-152Dig Dis Sci6230503058201710.1007/s10620-017-4759-828921383 LiXZhouYQianHCCAT1 expressed in malignant and pre-malignant human gastric tissuesCell Mol Biol (Noisy-le-grand)638993201710.14715/cmb/2017.63.5.1628719351 ShangAWangWGuCChenWLuWSunZLiDLong non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expressionAging (Albany NY)1283018320202010.18632/aging.10313932380476 GuglielmiSD'AngeloFBichardPLepilliezVFrossardJLGastric intestinal metaplasia and cancer risk: How to follow?Rev Med Suisse15150215052019(In French)31496174 SongYYangHLinRJiangKWangBMThe role of ferroptosis in digestive system cancerOncol Lett1821592164201931402933 SongYYeMZhouJWangZZhuXTargeting E-cadherin expression with small molecules for digestive cancer treatmentAm J Transl Res1139323944201931396310 Montalvo-JaveEERahnemai-AzarAAPapaconstantinouDDeloizaMETsilimigrasDIMorisDMendoza-BarreraGEWeberSMPawlikTMMolecular pathways and potential biomarkers in gallbladder cancer: A comprehensive reviewSurg Oncol318389201910.1016/j.suronc.2019.09.00631541911 RamnarineVRKobelevMGibbEANouriMLinDWangYButtyanRDavicioniEZoubeidiACollinsCCThe evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease managementEur Urol76546559201910.1016/j.eururo.2019.07.04031445843 ZhouDDLiuXFLuCWPantOPLiuXDLong non-coding RNA PVT1: Emerging biomarker in digestive system cancerCell Prolif50e12398201710.1111/cpr.1239829027279 GuoJMaYPengXJinHLiuJLncRNA CCAT1 promotes autophagy via regulating ATG7 by sponging miR-181 in hepatocellular carcinomaJ Cell Biochem1201797517983201910.1002/jcb.2906431218739 AbediniPFattahiAAgahSTalebiABeygiAHAminiSMMirzaeiAAkbariAExpression analysis of circulating plasma long noncoding RNAs in colorectal cancer: The relevance of lncRNAs ATB and CCAT1 as potential clinical hallmarksJ Cell Physiol2342202822033201910.1002/jcp.2876531093977 YangCPanYDengSPDownregulation of lncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cellsBMC Mol Cell Biol209201910.1186/s12860-019-0188-131039730 ZhangJCaiMJiangDXuLUpregulated LncRNA-CCAT1 promotes hepatocellular carcinoma progression by functioning as miR-30c-2-3p spongeCell Biochem Funct378492201910.1002/cbf.337530773676 FangHLiuHMWuWHLiuHPanYLiWJUpregulation of long noncoding RNA CCAT1-L promotes epithelial-mesenchymal transition in gastric adenocarcinomaOnco Targets Ther1156475655201810.2147/OTT.S17055330254457 LiNJiangKFangLPYaoLLYuZKnockdown of long noncoding RNA CCAT1 inhibits cell growth, invasion and peritoneal metastasis via downregulation of Bmi-1 in gastric cancerNeoplasma65736744201810.4149/neo_2018_171206N80129940756 HuMZhangQTianXHWangJLNiuYXLiGlncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axisMol Carcinog5822072217201910.1002/mc.2310931544294 ShiDWuFGaoFQingXShaoZPrognostic value of long non-coding RNA CCAT1 expression in patients with cancer: A meta-analysisPLoS One12e0179346201710.1371/journal.pone.017934628594897 CaoWChenHDYuYWLiNChenWQChanging profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020Chin Med J (Engl)134783791202110.1097/CM9.000000000000147433734139

Flow chart representing the literature search and selection process.

Forest plot of studies evaluating the relationship between colon cancer associated transcript-1 expression and clinicopathological variables. (A) Age, (B) sex, (C) depth of infiltration and (D) tumor size. CI, confidence interval; OR, odds ratio.

Forest plot of studies evaluating the relationship between colon cancer associated transcript-1 expression and clinicopathological variables. (A) Differentiation, (B) lymph node metastasis and (C) TNM stage. CI, confidence interval; OR, odds ratio.

Forest plot for the correlation between colon cancer associated transcript-1 expression and survival outcomes. CI, confidence interval; OR, odds ratio; OS, overall survival; RFS, recurrence-free survival.

Funnel plot analysis of potential publication bias in the present study (Begg's test) regarding (A) age, (B) sex, (C) depth of infiltration and (D) tumor size. s.e. of: logor, standard error of OR logarithm; s.e. of: lnhr, standard error of HR logarithm.

Funnel plot analysis of potential publication bias in the present study (Begg's test) regarding (A) differentiation, (B) lymph node metastasis, (C) TNM stage and (D) overall survival.

Sensitivity analysis to determine whether an individual study influenced the (A) age, (B) sex, (C) depth of infiltration or (D) tumor size pooled results. CI, confidence interval.

Sensitivity analysis to determine whether an individual study influenced the (A) differentiation, (B) lymph node metastasis, (C) TNM stage or (D) overall survival pooled results. CI, confidence interval.

Basic information of the studies included in the meta-analysis.

First author, year Country Cancer type CCAT1 detection method Survival information Newcastle-Ottawa Scale score (Refs.)
He et al, 2014 China CC RT-qPCR OS 6 (30)
Zhu et al, 2015 China HCC RT-qPCR OS, RFS 7 (31)
Deng et al, 2015 China HCC RT-qPCR OS, RFS 7 (33)
McCleland et al, 2016 USA CRC RT-qPCR OS 8 (37)
Wang et al, 2017 China HCC RT-qPCR OS, DFS 8 (36)
Zhang E et al, 2017 China ESCC RT-qPCR OS 8 (38)
Jiang et al, 2017 China CCA RT-qPCR OS 6 (34)
Ozawa et al, 2017 USA CRC RT-qPCR OS, RFS 8 (35)
Liu and Shangguan, 2017 China GC RT-qPCR OS, RFS 8 (32)
Zhang et al, 2017 China CCA RT-qPCR NA 7 (39)
Li et al, 2017 China GC RT-qPCR NA 8 (40)
Shang et al, 2020 China CRC RT-qPCR NA 7 (41)

CC, colon cancer; CCA, cholangiocarcinoma; CCAT1, colon cancer associated transcript-1; CRC, colorectal cancer; DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival; RT-qPCR, reverse transcription-quantitative PCR; NA, (data) not available.

Characteristics of the studies included in the meta-analysis.

Colon cancer associated transcript-1 expression level
High Low
First author, year Total patients, n LNM staging, n Age ≥60 years, n T1/2 stage, n HTS, n TS>5, n LD, n M, n Total patients, n LNM staging, n Age ≥60 years, n T1/2 stage, n HTS, n TS>5, n LD, n M, n (Refs.)
He et al, 2014 24 15 10 NA 15 17 NA 14 24 6 13 NA 5 8 NA 9 (30)
Zhu et al, 2015 43 NA NA NA NA NA NA NA 43 NA NA NA NA NA NA NA (31)
Deng et al, 2015 33 NA 8 NA NA 20 NA 27 33 NA 10 NA NA 10 NA 25 (33)
McCleland et al, 2016 202 NA 107 NA 107 NA NA 113 436 NA 233 NA 175 NA NA 213 (37)
Wang et al, 2017 60 NA 29 NA 44 36 NA 40 37 NA 16 NA 9 15 NA 18 (36)
Zhang et al, 2017 45 29 26 17 29 NA 27 25 45 19 22 23 15 NA 22 24 (38)
Jiang et al, 2017 47 33 27 NA 34 NA 23 27 44 19 29 NA 19 NA 10 26 (34)
Ozawa et al, 2017 55 37 NA 11 38 20 3 35 70 32 NA 16 34 27 2 35 (35)
Liu and Shangguan, 2017 121 80 61 NA 73 80 63 45 119 54 70 NA 49 69 36 50 (32)
Zhang S et al, 2017 65 48 35 16 49 NA NA 27 55 16 35 38 17 NA NA 27 (39)
Li et al, 2017 41 31 35 9 19 16 23 17 27 12 25 10 23 11 22 23 (40)
Shang et al, 2020 NA 29 NA NA 14 NA NA 12 NA 8 NA NA 7 NA NA 13 (41)

HTS, high TNM stage (III/IV); LD, low differentiation; LNM, lymph-node-metastasis; M, male; T1/2, tumor stage 1/2; TS>5, tumor stage >5; NA, (data) not available.

Pooled ORs for the association between colon cancer associated transcript-1 expression levels and clinicopathological parameters in the meta-analysis.

Heterogeneity
Clinicopathological features Number of studies Number of patients Pooled OR (95% CI) P-value I2 (%) P-value Model used
Age 9 1,268 0.91 (0.73-1.12) 0.369 0.00 0.867 Random
Sex 11 1,633 1.16 (0.95-1.42) 0.156 9.30 0.355 Random
Depth of infiltration 4 403 1.95 (0.79-4.84) 0.147 75.90 0.006 Random
Tumor size 6 644 1.81 (1.31-2.48) <0.001 49.60 0.078 Random
Differentiation 5 596 0.45 (0.31-0.64) <0.001 0.00 0.750 Random
Lymph node metastasis 7 782 3.14 (2.34-4.21) <0.001 9.80 0.354 Random
TNM stage 10 1,567 3.08 (2.07-4.59) <0.001 62.00 0.005 Random

OR, odds ratio; CI, confidence interval.

Related survival data of enrolled studies in the meta-analysis.

Related information on survival
Overall survival Recurrence-free survival
First author, year Cancer type Sample size
HR estimation method (Refs.)
Univariate Multivariate Univariate Multivariate
He et al, 2014 CC 48 2.34 (1.32-4.17) NA NA NA KM (30)
Zhu et al, 2015 HCC 86 3.33 (1.60-6.96) 3.33 (1.60-6.96) NA NA Rep (31)
Deng et al, 2015 HCC 66 2.11 (0.88-5.15) NA 1.97(1.04-3.70) NA KM (33)
McCleland et al, 2016 CRC 638 2.31 (2.01-2.65) NA NA NA KM (37)
Wang et al, 2017 HCC 97 3.27 (1.62-6.27) 2.98 (1.32-3.95) NA NA Rep (36)
Zhang et al, 2017 ESCC 90 2.22 (1.35-3.66) NA NA NA KM (38)
Jiang et al, 2017 CCA 91 3.14 (1.97-5.01) 2.25 (1.40-3.63) NA NA Rep (34)
Ozawa et al, 2017 CRC 125 NA 5.90 (2.09-24.70) NA 2.52 (1.07-5.56) Rep (35)
Liu and Shangguan, 2017 GC 240 2.16 (0.98-6.65) 2.41 (1.13-5.94) NA NA Rep (32)

CC, colon cancer; CCA, cholangiocarcinoma; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HR, hazard ratio; KM, Kaplan-Meier; NA, not applicable; Rep, reported.